Sadoff Investment Management adds Amgen (AMGN) to its portfolio

Amgen (AMGN) : Sadoff Investment Management added new position in Amgen during the most recent quarter end. The investment management firm now holds 1,317 shares of Amgen which is valued at $220,598 , the company said in a statement filed on Oct 7, 2016 with the SEC.Amgen makes up approximately 0.02% of Sadoff Investment Management’s portfolio.

Other Hedge Funds, Including , Central Bank Trust Co reduced its stake in AMGN by selling 283 shares or 2.34% in the most recent quarter. The Hedge Fund company now holds 11,820 shares of AMGN which is valued at $1,979,850. Amgen makes up approx 0.56% of Central Bank Trust Co’s portfolio.Private Asset Management Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 1,630 shares of Amgen which is valued at $272,601. Amgen makes up approx 0.05% of Private Asset Management Inc’s portfolio.First American Trust Fsb reduced its stake in AMGN by selling 575 shares or 2.82% in the most recent quarter. The Hedge Fund company now holds 19,820 shares of AMGN which is valued at $3,314,697. Amgen makes up approx 1.04% of First American Trust Fsb’s portfolio. Lvm Capital Management Ltdmi sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 69,845 shares of AMGN which is valued $11,680,878.Beacon Financial Group boosted its stake in AMGN in the latest quarter, The investment management firm added 2,834 additional shares and now holds a total of 4,339 shares of Amgen which is valued at $725,654. Amgen makes up approx 0.15% of Beacon Financial Group’s portfolio.

Amgen opened for trading at $167.94 and hit $168.1499 on the upside on Friday, eventually ending the session at $167.5, with a gain of 0.36% or 0.6 points. The heightened volatility saw the trading volume jump to 16,79,823 shares. Company has a market cap of $125,350 M.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.